Charmacy Pharmaceutical Co., Ltd.

SEHK:2289 주식 보고서

시가총액: HK$972.0m

Charmacy Pharmaceutical 대차 대조표 상태

재무 상태 기준 확인 2/6

Charmacy Pharmaceutical has a total shareholder equity of CN¥592.2M and total debt of CN¥948.8M, which brings its debt-to-equity ratio to 160.2%. Its total assets and total liabilities are CN¥3.3B and CN¥2.7B respectively. Charmacy Pharmaceutical's EBIT is CN¥129.4M making its interest coverage ratio 2.5. It has cash and short-term investments of CN¥417.4M.

주요 정보

160.2%

부채 비율

CN¥948.84m

부채

이자 보상 비율2.5x
현금CN¥417.41m
주식CN¥592.15m
총 부채CN¥2.68b
총 자산CN¥3.27b

최근 재무 상태 업데이트

Recent updates

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

May 13
There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

Apr 24
There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jan 19
Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well

Oct 25
These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well

If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity

Sep 17
If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity

Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?

May 02
Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?

What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Mar 15
What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?

Feb 17
Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?

We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide

Jan 27
We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide

Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture

Jan 09
Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture

What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us

Dec 22
What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us

Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years

Nov 29
Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years

재무 상태 분석

단기부채: 2289's short term assets (CN¥2.8B) exceed its short term liabilities (CN¥2.6B).

장기 부채: 2289's short term assets (CN¥2.8B) exceed its long term liabilities (CN¥40.5M).


부채 대 자본 내역 및 분석

부채 수준: 2289's net debt to equity ratio (89.7%) is considered high.

부채 감소: 2289's debt to equity ratio has increased from 108.8% to 160.2% over the past 5 years.

부채 범위: 2289's operating cash flow is negative, therefore debt is not well covered.

이자 보장: 2289's interest payments on its debt are not well covered by EBIT (2.5x coverage).


대차 대조표


건강한 기업 발견하기